SELLAS Life Sciences Group, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDSELLAS Life Sciences Group, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 99), indicating clear outperformance against the broad market. Earnings growth of 26% provides fundamental context to the price action. However, price is extended 66% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $10.25 | +31.68% | ABOVE |
| 50 SMA | $8.15 | +65.63% | ABOVE |
| 100 SMA | $6.47 | +108.73% | ABOVE |
| 150 SMA | $5.39 | +150.49% | ABOVE |
| 200 SMA | $4.48 | +201.46% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is SLS in an uptrend right now?
SLS has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, SLS is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is SLS overbought or oversold?
SLS's RSI (14) is 67. The stock is in neutral territory, neither overbought nor oversold.
Is SLS outperforming the market?
SLS has a Relative Strength (RS) Rating of 99 out of 99. Yes, SLS is a market leader, outperforming 99% of all stocks over the past 12 months.
Where is SLS in its 52-week range?
SLS is trading at $13.50, which is 85% of its 52-week high ($15.88) and 84% above its 52-week low ($1.39).
How volatile is SLS?
SLS has a Beta of 1.78 and 52-week volatility of 101%. It's more volatile than the S&P 500 - expect bigger swings.